Skip to content

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

 
  • EnEn
  • SvSv
  • About us
    • Management
    • Board of Directors
  • Therapeutic areas
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Orviglance® (Mangoral)
    • Oncoral
  • Partnering
  • IR & Media
    • Press releases
    • Financial Reports
    • Presentations & articles
    • Share
    • Shareholders
    • Insiders
    • Equity research
    • Financial calendar
    • Events
    • IR Contact
    • Prospectuses
    • CMD 2020
    • Subscribe to press releases
  • Governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Our values
    • Meet us
  • Contact
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Subscribe to press releases
All All press releasesRegulatory press releasesFinancial reports
Regulatory
2022-12-06 | New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2022-03-07 | Ascelia Pharma suspends clinical activities in Russia
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2021-09-21 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2021-08-18 | Covid-19 extends recruitment period of SPARKLE study
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2021-03-17 | Ascelia Pharma has carried out a directed new share issue raising SEK 200 million
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2021-03-17 | Ascelia Pharma intends to carry out a directed new share issue
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-05-20 | Updated SPARKLE timelines due to Covid-19 impact
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-05-06 | First participant enrolled in the clinical hepatic impairment study with Mangoral
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-02-19 | First patient enrolled in pivotal Phase III clinical study SPARKLE with lead candidate Mangoral
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2019-06-10 | Ascelia Pharma strengthens its Mangoral franchise by filing of a patent application for next generation Mangoral product
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2019-05-07 | Ascelia Pharma received supportive feedback from EMA on the phase 3 program for Mangoral®
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2019-04-12 | Exercise of over-allotment option, stabilisation notice and end of the stabilisation period
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2019-04-11 | Stabilisation notice
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2019-04-08 | Encouraging results from the Phase I combination study with Oncoral and oral capecitabine published in the journal Cancer Chemotherapy and Pharmacology
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2019-04-01 | Stabilisation notice
PDF
Report
Financial Data
Presentation
Webcast

Posts navigation

Older posts
Learn more

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. […]
Learn more

Meet us

Ascelia’s employees are passionate and driven to develop products that will help people with rare cancer conditions live longer and healthier lives.
Learn more

Our values

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical […]
  1. Start

About us

  • Start
  • About us
  • Career
  • Contact
  • Privacy policy
  • About cookies
  • Cookie settings

Pipeline

  • Oncoral
  • Orviglance®

IR & Media

  • Subscribe to press releases
  • Press releases & News
  • Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Follow us

 

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

© Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance.

Video
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all